Expired CME Article
Importance of Hepatitis Vaccination in Patients with Chronic Liver Disease
Abstract
Acute hepatitis A or B infection can be lethal in patients with chronic liver disease. Safe and effective vaccines are currently available to prevent hepatitis A and B. Despite wide availability of vaccines, most patients with chronic liver disease are not immunized, in part due to nonuniform and inconsistent current recommendations for this population. A better understanding of the importance of preventing acute hepatitis A and B in patients with chronic liver disease and a proactive approach to vaccination by primary care physicians can positively influence the outcome of patients with chronic liver disease.This content is limited to qualifying members.
Existing members, please login first
If you have an existing account please login now to access this article or view purchase options.
Purchase only this article ($25)
Create a free account, then purchase this article to download or access it online for 24 hours.
Purchase an SMJ online subscription ($75)
Create a free account, then purchase a subscription to get complete access to all articles for a full year.
Purchase a membership plan (fees vary)
Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.
References
1. Kung HC, Hoyert DL, Xu J, et al. National Vital Statistics Reports. Atlanta, Centers for Disease Control and Prevention, 2008, vol 56.
2. Bell BP, Navarro VJ, Manos MM, et al. The epidemiology of newly-diagnosed chronic liver disease in the United States: findings of population-based sentinel surveillance. Hepatology 2001;34:468A.
3. Margolis HS, Coleman PJ, Brown RE, et al. Prevention of hepatitis B virus transmission by immunization. An economic analysis of current recommendations. JAMA 1995;274:1201–1208.
4. Armstrong GL, Wasley A, Simard EP, et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006;144:705–714.
5. Margolis HS, Coleman PJ, Brown RE, et al. Prevention of hepatitis B virus transmission by immunization: An economic analysis of current recommendations. JAMA 1995;274:1201–1208.
6. Recommendations for the prevention and control of hepatitis C virus infection and HCV-related chronic disease. Centers for Disease Control and Prevention. MMWR Recomm Rep 1998;47:1–39.
7. Reiss G, Keeffe EB. Review article: hepatitis vaccination in patients with chronic liver disease. Aliment Pharmacol Ther 2004;19:715–727.
8. Cooksley WG. What did we learn from the Shanghai hepatitis A epidemic? J Viral Hepat 2000;7(suppl 1):1–3.
9. Cooksley WG. Consensus statement on the role of hepatitis A vaccination in patients with chronic liver disease. J Viral Hepat 2000;suppl 1:29–30.
10. Yao G. Clinical spectrum and natural history of viral hepatitis A in a 1988 Shanghai epidemic, in Hollinger FB, Lemon SM, Margolis HS (eds): Viral Hepatitis and Liver Disease. Baltimore, Williams and Williams, 1991, pp 76–78.
11. Keeffe EB. Is hepatitis A more severe in patients with chronic hepatitis B and other chronic liver diseases? Am J Gastroenterol 1995;90:201–205.
12. Fukumoto Y, Okita K, Konishi T, et al. Hepatitis A infection in chronic carriers of hepatitis B virus, in Sung J-L, Chen D-S (eds): Viral Hepatitis and Hepatocellular Carcinoma. Amsterdam, Excerpta Medica, 1990, pp 43–48.
13. Yang CY, Chu CM, Liaw YF, et al. [A clinical study on acute hepatitis A—with special reference to its occurrence in HBsAg carriers]. Taiwan Yi Xue Hui Za Zhi 1983;82:1126–1132.
14. Tassopoulos N, Papaevangelou G, Roumeliotou-Karayannis A, et al. Double infections with hepatitis A and B viruses. Liver 1985;5:348–353.
15. Zachoval R, Roggendorf M, Deinhardt F. Hepatitis A infection in chronic carriers of hepatitis B virus. Hepatology 1983;3:528–531.
16. Viola LA, Barrison IG, Coleman JC, et al. The clinical course of acute type A hepatitis in chronic HBsAg carriers—a report of 3 cases. Postgrad Med J 1982;58:80–81.
17. Conteas C, Kao H, Rakela J, et al. Acute type A hepatitis in three patients with chronic HBV infection. Dig Dis Sci 1983;28:684–686.
18. Vento S, Garofano T, Renzini C, et al. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. N Engl J Med 1998;338:286–290.
19. Féray C, Gigou M, Samuel D, et al. Hepatitis C virus RNA and hepatitis B virus DNA in serum and liver of patients with fulminant hepatitis. Gastroenterology 1993;104:549–555.
20. Mohamed Ael S, al Karawi MA, Mesa GA. Dual infection with hepatitis C and B viruses: clinical and histological study in Saudi patients. Hepatogastroenterology 1997;44:1404–1406.
21. Benvegnù L, Fattovich G, Noventa F, et al. Concurrent hepatitis B and C virus infection and risk of hepatocellular carcinoma in cirrhosis. A prospective study. Cancer 1994;74:2442–2448.
22. Sagnelli E, Coppola N, Scolastico C, et al. Virologic and clinical expressions of reciprocal inhibitory effect of hepatitis B, C, and delta viruses in patients with chronic hepatitis. Hepatology 2000;32:1106–1110.
23. Keeffe EB, Iwarson S, McMahon BJ, et al. Safety and immunogenicity of hepatitis A vaccine in patients with chronic liver disease. Hepatology 1998;27:881–886.
24. Lee SD, Chan SY, Yu MI, et al. Safety and immunogenicity of hepatitis A vaccine in patients with chronic liver disease. J Med Virol 1997;52:215–218.
25. Wiedmann M, Liebert UG, Oesen U, et al. Decreased immunogenicity of recombinant PubMed | CrossRef
26. Lee SD, Chan YC, Yu MI, et al. Hepatitis B vaccination in patients with chronic hepatitis C. J Med Virol 1999;59:463–468.
27. Rosman AS, Basu P, Galvin K, et al. Efficacy of a high and accelerated dose of hepatitis B vaccine in alcoholic patients: a randomized clinical trial. Am J Med 1997;103:217–222.
28. Beran J, Dedek P, Stepánová V, et al. Safety and immunogenicity of a combined vaccine against hepatitis A and B in patients with autoimmune hepatitis. Cent Eur J Public Health 2005;13:20–23.
29. Hadler SC, Margolis HS, Hepatitis B. Immunization: vaccine types, efficacy, and indications for immunization, in Remington JS, Swartz MN (eds): Current clinical topics in infectious diseases. Boston, Blackwell Scientific, 1992, pp 282–308.
30. Coates RA, Halliday ML, Rankin JG, et al. Immunogenicity and safety of a yeast-derived recombinant DNA hepatitis B vaccine in health care workers, in Zuckerman A (ed): Viral Hepatitis and Liver Disease. New York, AR Liss, 1988, pp 1038–1042.
31. Pasricha N, Datta U, Chawla Y, et al. Poor responses to recombinant HBV vaccination in patients with HIV infection. Trop Gastroenterol 2005;26:178–182.
32. Corrao G, Calleri M, Zotti M, et al. Immune response to anti-HBV vaccination: study of conditioning factors. Eur J Epidemiol 1988;4:492–496.
33. Yu AS, Cheung RC, Keeffe EB. Hepatitis B vaccines. Clin Liver Dis 2004;8:283–300.
34. Girndt M, Köhler H. Hepatitis B virus infection in hemodialysis patients. Semin Nephrol 2002;22:340–350.
35. Mattos AA, Gomes EB, Tovo CV, et al. Hepatitis B vaccine efficacy in patients with chronic liver disease by hepatitis C virus. Arq Gastroenterol 2004;41:180–184.
36. Idilman R, De MN, Colantoni A, et al. The effect of high dose and short interval HBV vaccination in individuals with chronic hepatitis C. Am J Gastroenterol 2002;97:435–439.
37. Aziz A, Aziz S, Li DS, et al. Efficacy of repeated high-dose hepatitis B vaccine (80 microg) in patients with chronic liver disease. J Viral Hepat 2006;13:217–221.
38. Smallwood GA, Coloura CT, Martinez E, et al. Can patients awaiting liver transplantation elicit an immune response to the hepatitis A vaccine? Transplant Proc 2002;34:3289–3290.
39. Arguedas MR, Johnson A, Eloubeidi MA, et al. Immunogenicity of hepatitis A vaccination in decompensated cirrhotic patients. Hepatology 2001;34:28–31.
40. Dumot JA, Barnes DS, Younossi Z, et al. Immunogenicity of hepatitis A vaccine in decompensated liver disease. Am J Gastroenterol 1999;94:1601–1604.
41. Chalasani N, Smallwood G, Halcomb J, et al. Is vaccination against hepatitis B infection indicated in patients waiting for or after orthotopic liver transplantation? Liver Transpl Surg 1998;4:185–187.
42. Horlander JC, Boyle N, Manam R, et al. Vaccination against hepatitis B in patients with chronic liver disease awaiting liver transplantation. Am J Med Sci 1999;318:304–307.
43. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1999;48:1–37.
44. Lok ASF, McMahon BJ. AASLD practice guidelines: chronic hepatitis B. Available at: http://www.aasld.org/practiceguidelines/Documents/Bookmarked%20Practice%20Guidelines/Corrections%20to%20Guidelines%20on%20Chronic%20Hep%20B.pdf. Accessed March 26, 2010.
45. Strader DB, Wright T, Thomas DL, et al; American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004;39:1147–1171.
46. NIH consensus statement on management of hepatitis C: 2002. NIH Consens State Sci Statements 2002;19:1–46.
47. Duncan M, Hirota WK, Tsuchida A. Prescreening versus empirical immunization for hepatitis A in patients with chronic liver disease: a prospective cost analysis. Am J Gastroenterol 2002;97:1792–1795.
48. Saab S, Martin P, Yee HF Jr. A simple cost-decision analysis model comparing two strategies for hepatitis A vaccination. Am J Med 2000;109:241–244.
49. Siddiqui F, Mutchnick M, Kinzie J, et al. Prevalence of hepatitis A virus and hepatitis B virus immunity in patients with polymerase chain reaction-confirmed hepatitis C: implications for vaccination strategy. Am J Gastroenterol 2001;96:858–863.
50. Blostein J, Clark PA. Cost-effectiveness of preimmunization hepatitis B screening in high-risk adolescents. Public Health Rep 2001;116:165–168.
51. Lau DT, Hewlett AT. Screening for hepatitis A and B antibodies in patients with chronic liver disease. Am J Med 2005;118(suppl):28S–33S.
52. Hoofnagle JH, Schafer DF. Serological markers of hepatitis B virus infection. Semin Liver Dis 1986;6:1–10.
53. Lemon SM, Thomas DL. Vaccines to prevent viral hepatitis. N Engl J Med 1997;336:196–204.
54. Recommended Adult Immunization Schedule—United States, 2010. MMWR Morb Mortal Wkly Rep 2010;59:1–4. Available at: http://www.cdc.gov/mmwr/PDF/wk/mm5901-Immunization.pdf. Accessed March 27, 2010.
55. Shim M, Khaykis I, Park J, et al. Susceptibility to hepatitis A in patients with chronic liver disease due to hepatitis C virus infection: missed opportunities for vaccination. Hepatology 2005;42:688–695.
